ClinicalTrials.gg
WithdrawnNCT07318350FORASMAUpdated Oct 23, 2026

Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)

A Phase 3 interventional study of N0783 and Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) in Moderate Asthma, sponsored by Eurofarma Laboratorios S.A.. Withdrawn. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Strategic change in development priorities.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 3, multicenter, randomized, parallel-group, open-label, non-inferiority clinical trial designed to evaluate the efficacy and safety of N0783 compared to Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) in the treatment of moderate asthma. Adult patients diagnosed with moderate asthma according to clinical and functional criteria will be enrolled. The primary objective is to demonstrate that N0783 is not inferior to Alenia® in improving asthma control. Participants will receive treatment according to the assigned intervention and will be monitored through scheduled visits for assessment of lung function, symptom control, and safety parameters throughout the study period.

02

Conditions studied

  • Moderate Asthma

Browse trials for

Keywords

  • Asthma
  • Moderate Asthma
  • Alenia®
  • Non-inferiority
  • Randomized Clinical Trial
  • Phase 3
03

In context

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Lead sponsor

Eurofarma Laboratorios S.A. is the lead sponsor of 64 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 12 and ≤ 65 years at Screening.
  • History of recurrent asthma symptoms (cough, wheezing, shortness of breath, chest tightness).
  • Previous medical diagnosis of asthma (confirmed by records, prescriptions, or participant report).
  • Documented reversible airway obstruction by spirometry: increase ≥ 200 mL and ≥ 12% post-bronchodilator (at screening or prior report).
  • Moderate asthma (GINA step 3) for ≥ 6 months, clinically stable and controlled with LABA + low-dose inhaled for ≥ 90 days.
  • ACQ-7 score ≤ 0.75 at Screening.
  • At Randomization: ACQ-7 score ≤ 0.75 and ≥ 70% adherence during run-in.

Exclusion criteria

Exclusion Criteria:

  • Moderate/severe asthma exacerbation within 90 days prior to screening.
  • Other pulmonary disease (including predominant ).
  • Symptomatic acute or chronic respiratory infection.
  • ≥ 40 kg/m².
  • Use of LAMA within 6 months prior to screening.
  • Oral or depot within 30 days prior to screening.
  • Biologic therapy for asthma, allergic rhinitis, or urticaria within 12 months prior to screening.
  • Systemic vasoconstrictors within 7 days prior to screening.
  • Known to formoterol, fluticasone, budesonide, or any component of study drugs.
  • Active pulmonary tuberculosis or fungal airway infection.
  • History or presence of ischemic heart disease, severe arrhythmias, cardiac decompensation, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm, pheochromocytoma, hypertrophic obstructive cardiomyopathy, thyrotoxicosis, > 450 ms.
  • History of hyperthyroidism or uncontrolled diabetes mellitus.
  • Severe or uncontrolled disease at investigator's discretion.
  • Pregnancy or breastfeeding; women of not using effective .
  • Participation in another clinical trial within 12 months unless direct benefit expected.
  • Any condition making participant unsuitable for study per investigator.
  • At Randomization: asthma exacerbation during run-in, prohibited medication use, ≥ 10%, TSH below normal, or AST > 2× , serum potassium below normal, severe renal impairment ( \< 30 mL/min/1.73m²), changes or QTc > 450 ms, or any abnormality making participant unsuitable.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    N0783

    Participants will receive N0783 administered via inhalation according to the dosing regimen specified in the protocol for the treatment of moderate asthma.

    Drug: N0783

  • Active comparator
    Alenia®

    Participants will receive Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) administered via inhalation according to the dosing regimen specified in the protocol for the treatment of moderate asthma.

    Drug: Alenia® (Formoterol 6 mcg / Budesonide 200 mcg)

Interventions

  • DrugN0783

    N0783 is a fixed-dose combination administered via inhalation using a metered-dose inhaler. Participants will receive the study drug according to the dosing regimen specified in the protocol for the treatment of moderate asthma.

  • DrugAlenia® (Formoterol 6 mcg / Budesonide 200 mcg)

    Drug page: Formoterol

    Alenia® is a fixed-dose combination of Formoterol 6 mcg and Budesonide 200 mcg administered via inhalation using a metered-dose inhaler. Participants will receive the comparator drug according to the dosing regimen specified in the protocol for the treatment of moderate asthma.

06

What researchers measure

Primary outcomes

  1. Absolute change in pre-bronchodilator FEV₁ (L) from baseline to Week 12

    Improvement in pre-bronchodilator forced expiratory volume in one second (FEV₁), assessed by spirometry. The absolute change in FEV₁ (in liters) will be measured at Week 12 (Final Visit) compared to baseline (Randomization Visit).

    Time frame: 12 weeks after treatment initiation

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Mar 2028, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 6, 2026
StartEst.
Oct 2026
Primary completionEst.
Mar 2028
CompletionEst.
Sep 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07318350
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion